Interestingly, the immune checkpoint inhibitor Ipilimumab (which targets cytotoxic T-lymphocyte-associated antigen-4, CTLA-4, the inhibitory receptor of CD8651 has been associated to immunotherapy complications such as Ipilimumab-associated colitis (Ipi-AC), an immune-mediated colitis that mimics inflammatory bowel disease52. This evidence concerns the gene CTLA4 and colitis.